Compare

BPC-157 vs Cerebrolysin

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

BPC-157

2443 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 67% · Mixed 18% · Unfavorable overall 15%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Skin appearance
-158
Appetite control
-32
Energy
-84
Mood
0
Focus
-102

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Headache
-62
GI discomfort
-133
Dizziness
-119
Fatigue
-5
Nausea
-103

Self-reported dose per injection

Median bucket: 0.6–1 mg · Most common: 0.6–1 mg

Reports span 0.05–5 mg

0.05–0.1 mg
4
0.1–0.2 mg
7
0.2–0.4 mg
12
0.4–0.6 mg
22
0.6–1 mg
31
1–2 mg
20
2–3 mg
11
3–5 mg
3

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing47stacking15side effects33bpc-15726

How repeat users are trending

Among repeat reporters, 62% said they felt similar to their last entry, 41% more positive, and 17% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 33 days · Based on 537 repeat reporters

Cerebrolysin

1329 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 63% · Mixed 20% · Unfavorable overall 17%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Lean mass
-136
Joint comfort
-119
Recovery
-72
Digestive comfort
-44
Skin appearance
-108

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Appetite loss
-40
Injection site reaction
-40
Anxiety
-107
Flushing
-48
Headache
-108

Self-reported dose per injection

Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg

Reports span 0.01–2 mg

0.01–0.025 mg
3
0.025–0.05 mg
11
0.05–0.1 mg
14
0.1–0.2 mg
19
0.2–0.4 mg
25
0.4–0.6 mg
17
0.6–1 mg
10
1–2 mg
7

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing13stacking11side effects29cerebrolysin12

How repeat users are trending

Among repeat reporters, 58% said they felt similar to their last entry, 31% more positive, and 13% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 29 days · Based on 292 repeat reporters

Sources (13)

Published sources linked on the BPC-157 and Cerebrolysin wiki pages.

  1. PubMed

    Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract

    Sikiric P, Seiwerth S, Rucman R, et al. Curr Pharm Des. 2018

    Source
    Wiki study page →
  2. PubMed

    Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts

    Chang CH, Tsai WC, Lin MS, et al. Molecules. 2019

    Source
    Wiki study page →
  3. PubMed

    BPC 157 and its role in accelerating wound healing

    Vukojevic J, Siroglavic M, Kasnik K, et al. Int J Mol Sci. 2022

    Source
    Wiki study page →
  4. ClinicalTrials.gov

    BPC-157 studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  5. PubMed

    BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing

    Seiwerth S, Rucman R, Turkovic B, et al. Current pharmaceutical design. 2018

    Source
    Wiki study page →
  6. PubMed

    Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions

    Ilic S, Drmic D, Franjic S, et al. Life sciences. 2011

    Source
    Wiki study page →
  7. PubMed

    Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain

    Lee E, Padgett B. Altern Ther Health Med. 2021

    Source
    Wiki study page →
  8. PubMed

    From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management

    Yuan C, Demers A, Silva-Ortiz V, et al. Int J Mol Sci. 2026

    Source
    Wiki study page →
  9. PubMed

    Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians

    Mayfield CK, Bolia IK, Feingold CL, et al. Am J Sports Med. 2026

    Source
    Wiki study page →
  10. PubMed

    Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions

    Rahman OF, Lee SJ, Seeds WA. JAAOS Glob Res Rev. 2026

    Source
    Wiki study page →
  11. PubMed

    Cerebrolysin for acute ischemic stroke (review)

    Chen N, Yang M, Guo J, et al. Cochrane Database Syst Rev. 2017

    Source
    Wiki study page →
  12. PubMed

    Cerebrolysin for acute ischaemic stroke

    Ziganshina LE, Abakumova T, Nurkhametova D, et al. The Cochrane database of systematic reviews. 2023

    Source
    Wiki study page →
  13. PubMed

    Cerebrolysin for acute ischaemic stroke

    Ziganshina LE, Abakumova T, Vernay L. The Cochrane database of systematic reviews. 2017

    Source
    Wiki study page →